POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER).
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates in solution to provide potassium ions and chloride ions.
| Metabolism | Potassium is not metabolized; it is primarily excreted by the kidneys (about 90%), with the remainder excreted in feces and small amounts in sweat. Renal excretion is regulated by aldosterone, acid-base balance, and potassium intake. |
| Excretion | Renal: >90% as potassium ion, with minimal biliary or fecal elimination (less than 10% total). |
| Half-life | Not applicable; potassium is a physiologic ion without classic elimination half-life. Steady-state distribution occurs within 6-8 hours of continuous infusion. Clinical context: half-life of potassium is determined by cellular uptake and renal excretion, with rapid redistribution in hypokalemic states. |
| Protein binding | Negligible (<2%); not significantly bound to plasma proteins. |
| Volume of Distribution | 0.5-0.7 L/kg; distributes predominantly in extracellular fluid, with gradual cellular uptake influenced by insulin and acid-base status. |
| Bioavailability | Oral: 90-100% as potassium chloride; IV: 100% (by definition). |
| Onset of Action | Intravenous: immediate (within minutes) for cardiac electrophysiologic effects; oral: 1-2 hours for increase in serum potassium. |
| Duration of Action | Intravenous: 2-4 hours after infusion for serum level elevation, but cellular repletion may require longer; oral: sustained effect over 6-12 hours. Clinical notes: Duration depends on dose, renal function, and degree of deficit. |
| Molecular Weight | 74.55 |
40 mEq intravenously over 4-6 hours, as needed. Maximum infusion rate: 10 mEq/hour, maximum concentration: 40 mEq/L.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 25-50% and monitor serum potassium; GFR < 10 mL/min: avoid or use with extreme caution with dose reduction of at least 50%. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor potassium levels due to risk of hyperkalemia in severe hepatic impairment. |
| Pediatric use | 0.25-0.5 mEq/kg/dose intravenously over 4-6 hours, up to 40 mEq/dose. Maximum infusion rate: 0.5 mEq/kg/hour. Dilute to ≤ 40 mEq/L. |
| Geriatric use | Start with lower doses (e.g., 20 mEq) and titrate slowly; monitor renal function and serum potassium frequently due to age-related decline in GFR. |
| 1st trimester | Potassium chloride is considered safe in usual therapeutic doses during the first trimester. However, hyperkalemia must be avoided as it can cause maternal cardiac arrhythmias and potential fetal hypoxia. Use only if clearly needed and monitor serum potassium levels closely. |
| 2nd trimester | Safe in usual therapeutic doses during the second trimester. Avoid hyperkalemia. Monitor serum potassium levels regularly. Use with caution in patients with renal impairment. |
| 3rd trimester | Safe in usual therapeutic doses during the third trimester. However, potassium requirements may increase due to fetal growth and maternal volume expansion. Avoid hyperkalemia. Monitor serum potassium levels, especially near term. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta by active transport and diffusion. Fetal serum potassium concentrations are maintained within a narrow range by placental regulation. Excessive maternal potassium can lead to fetal hyperkalemia. |
| Breastfeeding | Potassium is a normal constituent of breast milk and is actively secreted. Potassium chloride supplementation at usual doses is considered compatible with breastfeeding. However, maternal hyperkalemia may increase milk potassium levels; therefore, monitor maternal serum potassium if high doses are used. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is a normal constituent of body fluids. At therapeutic doses, no teratogenic effects have been reported. In overdose (hyperkalemia), fetal arrhythmias and death may occur. |
| Fetal Monitoring | Maternal serum potassium, renal function (BUN/creatinine), ECG for signs of hyper- or hypokalemia, fetal heart rate monitoring if maternal electrolyte disturbance is present. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. |
■ FDA Black Box Warning
Potassium chloride injections are concentrated and must be diluted before use. Accidental direct injection or infusion of undiluted potassium chloride can be fatal. Do not administer unless diluted and patient has adequate urine flow.
| Serious Effects |
HyperkalemiaSevere renal impairment (oliguria, anuria, or creatinine clearance <30 mL/min)Addison's disease (untreated)Acute dehydrationExtensive tissue breakdown (e.g., severe burns, trauma) – risk of hyperkalemiaConcurrent use of potassium-sparing diuretics or ACE inhibitors without careful monitoring
| Precautions | Risk of hyperkalemia: monitor serum potassium levels frequently, especially in patients with renal impairment, diabetes, or concurrent use of ACE inhibitors, ARBs, potassium-sparing diuretics, or other potassium-elevating drugs., Cardiac effects: hyperkalemia can cause cardiac arrhythmias, including fatal ventricular fibrillation. ECG monitoring is recommended., Use with caution in patients with cardiac disease, renal insufficiency, or conditions predisposing to hyperkalemia., Extravasation: intravenous administration can cause phlebitis and tissue necrosis if extravasation occurs., Avoid in patients with metabolic acidosis unless corrected. |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes, avocados, dried fruits) and potassium-containing salt substitutes to prevent hyperkalemia; maintain consistent dietary potassium intake; consult dietitian for meal planning. |
| Clinical Pearls | Administer via central line at a rate not exceeding 10 mEq/h to avoid phlebitis and hyperkalemia; mandatory cardiac monitoring during infusion; contraindicated in patients with severe renal impairment (CrCl <30 mL/min) or concurrent hyperkalemia; always confirm patency of IV line to prevent extravasation causing tissue necrosis. |
| Patient Advice | Do not stop or change the dose without consulting your doctor. · Report symptoms of hyperkalemia: muscle weakness, palpitations, numbness/tingling, or irregular heartbeat. · Avoid salt substitutes containing potassium or potassium-containing supplements unless directed. · Inform all healthcare providers that you are receiving potassium chloride. · This medication is for IV use only; do not take by mouth. |
Loading safety data…